The post approval study will enroll US female patients presenting with claudication or ischemic rest pain and an angiographically significant lesion in the superficial femoral or popliteal artery. Subjects are treated per Instructions For Use (IFU) with the Lutonix® Catheter. Subjects will have a Duplex Ultrasound (DUS) and clinical follow-up through two (2) years.
The Lutonix® 035 Drug Coated Balloon PTA Catheter (Lutonix® Catheter) has been approved by the Food and Drug Administration (P130024) for percutaneous transluminal angioplasty, after appropriate vessel preparation of de novo, restenotic, or in-stent restenotic lesions up to 300 mm in length in native superficial femoral or popliteal arteries with reference vessel diameters of 4-7 mm. The purpose of this post-approval study is to assess the safety and effectiveness of the Lutonix® Catheter in the US female population. This study will enroll approximately 165 female patients at a minimum of 10 US centers and a maximum of 25.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
4
Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.
St. Vincent Medical Group
Indianapolis, Indiana, United States
Midwest Cardiovascular Research Foundation
Davenport, Iowa, United States
Vascular Access Solutions
Orangeburg, South Carolina, United States
Wellmont CVA Heart Institute
Kingsport, Tennessee, United States
Number of Participants With Freedom From the Following: All-cause Peri-operative Death at 30 Days, Index Limb Amputation Within 1 Year, Index Limb Re-intervention Within 1 Year, and Index-limb-Related Death Within 1 Year Post Index Procedure
Index limb amputation includes above or below the ankle amputations.
Time frame: 12 months post index procedure
Effectiveness: Number of Participants With Primary Patency of the Target Lesion at 12 Month Post Index Procedure.
Primary patency is defined as freedom from target lesion restenosis (TLR) and from binary restenosis. Binary restenosis is adjudicated by the independent Core Laboratory based on Peak Systolic Velocity Ratio (PSVR) ≥ 2.5 and / or abnormal waveforms, or based on angiographic ≥ 50% diameter stenosis.
Time frame: 12 months post index procedure
Number of Participants With Freedom From All-cause Perioperative (≤ 30 Day) Death and Freedom From the Following: Index Limb Amputation, Index Limb Re-intervention, and Index-Limb-Related Death.
Time frame: 30 days post index procedure
Number of Major Vascular Complications at 30 Days Post Index Procedure
Time frame: 30 days
Number of Deaths (All Causes) at 30 Days Post Index Procedure
Time frame: 30 days post index procedure
Number of Participants With Clinically Driven Target Lesion Revascularization (TLR) at 1, 6, 12, and 24 Month Post Index Procedure
Time frame: 1, 6, 12 and 24 months post index procedure
Number of Participants With Target Vessel Revascularization (TVR) at 1, 6, 12, and 24 Months Post Index Porcedure
Time frame: 1, 6, 12 and 24 months post index procedure
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Number of Participants With Reintervention for Treatment of Thrombosis of the Target Vessel or Embolization to Its Distal Vasculature at 1, 6, 12, and 24 Months Post Index Procedure
Time frame: 1, 6, 12 and 24 months post index procedure
Number of Participants With Unanticipated and Anticipated Device Related Serious Adverse Events at 1, 6, 12, and 24 Months Post Index Procedure
Time frame: 1, 6, 12 and 24 months post index procedure
Number of Participants With Amputation (Above the Ankle)-Free Survival (AFS) at 1, 6, 12, and 24 Months Post Index Procedure.
Time frame: 1, 6, 12 and 24 months
Change in Rutherford Classification Scores at 1, 6, 12, and 24 Months Post Index Procedure Compared to Baseline
Time frame: 1, 6, 12 and 24 months post index procedure
Number of Participants With Sustained Clinical Benefit at 1, 6, 12, and 24 Months Post Index Procedure
Time frame: 1, 6, 12 and 24 months post index procedure
Change of Resting Ankle Brachial Index (ABI) Scores at 1, 6, 12, and 24 Months Post Index Procedure Compared to Baseline
Time frame: 1, 6, 12 and 24 months post index procedure